aTyr Pharma (NASDAQ:LIFE) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of aTyr Pharma (NASDAQ:LIFE) in a research report sent to investors on Friday morning, Benzinga reports. The firm currently has a $35.00 price target on the biotechnology company’s stock.

Separately, Royal Bank of Canada decreased their target price on aTyr Pharma from $19.00 to $16.00 and set an outperform rating for the company in a research report on Friday, March 15th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of Hold and an average price target of $23.67.

aTyr Pharma Trading Up 0.6 %

Shares of LIFE traded up $0.01 on Friday, reaching $1.61. 258,232 shares of the company’s stock were exchanged, compared to its average volume of 367,840. The business has a 50 day moving average price of $1.77 and a two-hundred day moving average price of $1.55. aTyr Pharma has a 12 month low of $1.08 and a 12 month high of $2.70. The stock has a market capitalization of $109.38 million, a P/E ratio of -1.79 and a beta of 1.27. The company has a current ratio of 6.27, a quick ratio of 6.27 and a debt-to-equity ratio of 0.02.

aTyr Pharma (NASDAQ:LIFE) last released its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01. The business had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.11 million. Research analysts anticipate that aTyr Pharma will post -0.97 earnings per share for the current year.

Institutional Investors Weigh In On aTyr Pharma

Several large investors have recently modified their holdings of LIFE. GSA Capital Partners LLP grew its position in shares of aTyr Pharma by 105.3% in the 1st quarter. GSA Capital Partners LLP now owns 224,147 shares of the biotechnology company’s stock valued at $437,000 after purchasing an additional 114,983 shares during the period. Kingswood Wealth Advisors LLC acquired a new stake in shares of aTyr Pharma during the first quarter worth $117,000. Pale Fire Capital SE lifted its position in aTyr Pharma by 425.8% in the 4th quarter. Pale Fire Capital SE now owns 293,706 shares of the biotechnology company’s stock valued at $414,000 after acquiring an additional 237,849 shares in the last quarter. Granite Bay Wealth Management LLC acquired a new position in aTyr Pharma in the 4th quarter worth $25,000. Finally, FMR LLC increased its holdings in aTyr Pharma by 5.1% during the 3rd quarter. FMR LLC now owns 8,556,925 shares of the biotechnology company’s stock worth $13,520,000 after purchasing an additional 413,162 shares in the last quarter. 61.72% of the stock is currently owned by institutional investors.

About aTyr Pharma

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.